在晚期细胞癌患者的免疫检查点抑制剂基组疗法后,功能和结果之间的关联
Hiroki Ishihara1, Yuki Nemoto2, Hidekazu Tachibana3
1Department of Urology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan.
Clinical genitourinary cancer
|January 28, 2024
概括
功能没有影响免疫检查点抑制剂 (ICI) 治疗在晚期癌中的有效性. 然而,安全性概况不同,IO-TKI组合显示慢性病 (CKD) 患者的不良事件增加.
科学领域:
- 在瘤学瘤学.
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- 基于免疫检查点抑制剂 (ICI) 治疗的晚期细胞癌 (RCC) 的结局对功能的影响尚不清楚.
- 慢性病 (CKD) 是晚期RCC患者常见的并发症.
研究的目的:
- 研究慢性病 (CKD) 级别对两种基于ICI的组合疗法 (IO-IO和IO-TKI) 在晚期细胞癌 (RCC) 患者的疗法的疗效和安全性的影响.
主要方法:
- 对167名晚期RCC患者进行了回顾性分析.
- 患者接受了双重免疫疗法 (IO-IO) 或免疫疗法加氨酸激酶抑制剂 (IO-TKI) 治疗.
- 根据CKD等级 (KDIGO 2012标准) 评估治疗结果.
主要成果:
- 在IO-IO和IO-TKI治疗方案中,所有CKD等级的疗效 (无进展生存率,总生存率,客观反应率) 均可比较.
- 在IO-IO组中,安全结果 (不良事件,治疗中断,皮质类固醇使用) 在CKD等级之间相似.
- 在IO-TKI组中,较高的CKD等级与显著增加的等级≥3不良事件以及增加ICI中断和皮质类固醇管理的趋势有关.
结论:
- 基于免疫检查点抑制剂 (ICI) 的组合疗法在晚期细胞癌 (RCC) 中,无论慢性病 (CKD) 程度如何,都显示出可比的疗效.
- 存在差异性的安全性概况,IO-TKI组合在与IO-IO相比,在CKD患者中显示出增加的毒性.
- 需要进一步的前性研究来验证这些发现.
相关概念视频
Factors Affecting Renal Clearance: Renal Impairment
95
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
95
Tumor Immunotherapy
526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


